ELISA – Webinars and Online Events
Webinar
Profiling Host Responses in COVID-19 Patients
On-Demand
This webinar explores how a next-generation automated ELISA technique can profile the dysregulated host response to COVID-19 in association with viral load in plasma.
Webinar
Automated Immunoassay Technology for Efficient Biomarker Detection
On-Demand
This webinar explores a highly sensitive, automated assay workflow to provide high-quality results for low-abundance biomarkers in serum, plasma and cerebrospinal fluid.
Webinar
Products & Services Across Cell Therapy Research & Development
On-Demand
Speaking at Cell & Gene Therapy 2023,Tracy Zhao from ACROBiosystems, presented their talk on products and services across cell therapy research and development.
Webinar
How to Select and Validate Host Cell Proteins for Process Development
On-Demand
Off-the-shelf generic and commercial Chinese hamster ovaries (CHO) host cell proteins (HCP) ELISAs are commonly used to quantitate HCP in early process development. However, it’s challenging to find and choose a generic ELISA suited to a process.
Webinar
Generation and Validation of CHO HCP ELISA
On-Demand
In bioprocessing, it is critical that host cell proteins (HCPs) can be identified, detected and removed so that the efficacy of the drug is not impacted, and custom process-specific HCP ELISA are typically the preferred method for measuring these contaminants.
Webinar
Formulating Cannabinoid Particles for Therapeutics
On-Demand
Join Dr Natalia Sannikova and Tomas Skrinskas from Ascension Sciences, as they explore the therapeutic use of cannabinoids as novel medicines and the opportunities of nanotechnology in formulating cannabinoid nanoparticles.
Webinar
Analysis of Process Related Impurities in Cell & Gene Therapy Products by SWATH LC-MS
On-Demand
The manufacturing process for cell and gene therapies is complex and can contain process-related impurities from multiple organisms. A commercial host cell protein (HCP)-ELISA kit is often not available for the cell line or is not suitable for the specific process due to a low HCP coverage. Development of a process-specific ELISA can be unfeasible as the product often requires a short development time.
Advertisement